Why the study?
Does early treatment with methylprednisolone and human immunoglobulin improve clinical, echocardiographic, and biomarker outcomes in a patient with coronavirus fulminant myocarditis?
Population
A 37-year-old male with coronavirus fulminant myocarditis, cardiogenic shock, and pulmonary infection
Design
Case report
Follow-up
3 weeks
Authors
Loading...
May support glucocorticoid plus immunoglobulin in COVID-19 fulminant myocarditis; hypothesis-generating without controlled data.
Does early treatment with methylprednisolone and human immunoglobulin improve clinical, echocardiographic, and biomarker outcomes in a patient with coronavirus fulminant myocarditis?
Early glucocorticoid anti-inflammatory therapy and immunoglobulin therapy may be effective in treating coronavirus fulminant myocarditis complicated by cardiogenic shock.
Hu et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: